Verastem directors buy $475K of stock, company set for potential pivotal trials
Three directors of cancer drug company Verastem Inc. and its founding executive chairman have purchased $475,000 worth of the company’s stock in the past week as it plans to start a potential pivotal trial against mesothelioma in coming months.
Login to comment.